OMDA Stock Analysis: Omada Health, Common Stock | NASDAQ
Health Information Services | NASDAQ, USA | Market Cap: 1.366m USD | 12M Return: 28% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 22.5M
Qual. Beats: 0
Rev. Trend: 99.7%
Warnings
Tailwinds
Seasonality 1.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Omada Health, Inc. (NASDAQ: OMDA) is a U.S. virtual care provider offering digital programs for cardiometabolic conditions (prediabetes, diabetes, and hypertension), musculoskeletal care, weight management, and behavioral health, along with dedicated support for members using GLP-1 agonists. The company sells its programs primarily on a business-to-business basis to employers, health plans and health systems, and pharmacy benefits managers, distributing through its direct sales force and channel partners.
Operating within the Health Care Technology sub-industry, Omada sits in the digital therapeutics and virtual care segment, delivering remote, app-based interventions as an alternative or complement to in-person care. Founded in 2011 and headquartered in South San Francisco, California, Omada completed its IPO in June 2025.
- GLP-1 support enrollment surges on Ozempic and Wegovy adoption
- Employer and health plan contract wins accelerate top-line growth
- Path to profitability questioned amid rising customer acquisition costs
| Net Income: -6.30m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 30.35 > 1.0 |
| NWC/Revenue: 70.86% < 20% (prev 28.12%; Δ 42.75% < -1%) |
| CFO/TA 0.07 > 3% & CFO 22.5m > Net Income -6.30m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 3.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.9m) vs 12m ago 5.70% < -2% |
| Gross Margin: 66.22% > 18% (prev 61.66%; Δ 4.57% > 0.5%) |
| Asset Turnover: 127.6% > 50% (prev 134.3%; Δ -6.73% > 0%) |
| Interest Coverage Ratio: -3.50 > 6 (EBIT TTM -5.17m / Interest Expense TTM 1.48m) |
| A: 0.66 (Total Current Assets 269.4m - Total Current Liabilities 68.7m) / Total Assets 302.8m |
| B: -1.52 (Retained Earnings -459.7m / Total Assets 302.8m) |
| C: -0.02 (EBIT TTM -5.17m / Avg Total Assets 222.0m) |
| D: 3.41 (Book Value of Equity 234.1m / Total Liabilities 68.7m) |
| Altman-Z'' = 2.82 = A |
| DSRI: 0.91 (Receivables 40.0m/29.3m, Revenue 283.3m/189.7m) |
| GMI: 0.93 (GM 61.66% / 66.22%) |
| AQI: 0.36 (AQ_t 0.08 / AQ_t-1 0.23) |
| SGI: 1.49 (Revenue 283.3m / 189.7m) |
| TATA: -0.10 (NI -6.30m - CFO 22.5m) / TA 302.8m) |
| Beneish M = -3.19 (Cap -4..+1) = AA |
As of July 17, 2026, the stock is trading at USD 23.67 with a total of 1,319,098 shares traded. Over the past week, the price has changed by +0.51%, over one month by +38.34%, over three months by +77.04% and over the past year by +27.95%.
Current recommended Stop Loss: 22.20 (which is 6.2% or 1.5 ATR below the current price).
Omada Health, Common Stock has no consensus analysts rating.
| Analysts Target Price | 22.9 | -3.2% |
P/E Forward = 769.2308
P/S = 4.8223
P/B = 5.6854
Revenue TTM = 283.3m USD
EBIT TTM = -5.17m USD
EBITDA TTM = 491k USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.15b USD (1.37b + (null Debt) - CCE 211.8m)
Interest Coverage Ratio = -3.50 (Ebit TTM -5.17m / Interest Expense TTM 1.48m)
EV/FCF = 60.69x (Enterprise Value 1.15b / FCF TTM 19.0m)
FCF Yield = 1.65% (FCF TTM 19.0m / Enterprise Value 1.15b)
FCF Margin = 6.71% (FCF TTM 19.0m / Revenue TTM 283.3m)
Net Margin = -2.22% (Net Income TTM -6.30m / Revenue TTM 283.3m)
Gross Margin = 66.22% ((Revenue TTM 283.3m - Cost of Revenue TTM 95.7m) / Revenue TTM)
Gross Margin QoQ = 62.39% (prev 70.75%)
Tobins Q-Ratio = 3.81 (Enterprise Value 1.15b / Total Assets 302.8m)
Interest Expense / Debt = unknown (Interest Expense 1.48m / Debt none)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -4.09m (EBIT -5.17m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.92 (Total Current Assets 269.4m / Total Current Liabilities 68.7m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 491k)
Debt / FCF = unknown (Net Debt none / FCF TTM 19.0m)
Total Stockholder Equity = 223.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.84% (Net Income -6.30m / Total Assets 302.8m)
RoE = -2.81% (Net Income TTM -6.30m / Total Stockholder Equity 223.8m)
RoCE = -2.21% (EBIT -5.17m / Capital Employed (Total Assets 302.8m - Current Liab 68.7m))
RoIC = -1.86% (negative operating profit) (NOPAT -4.09m / Invested Capital 220.0m)
WACC = 10.21% (E(1.37b)/V(1.37b) * Re(10.21%) + (debt-free company))
Discount Rate = 10.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.55 | Cagr: 2.50%
[DCF] Terminal Value 69.20% ; FCFF base≈19.0m ; Y1≈19.1m ; Y5≈20.2m
[DCF] Fair Price = 4.02 (EV 239.1m - Net Debt 0.0 = Equity 239.1m / Shares 59.4m; r=10.21% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.70 | # QB: 0
Revenue Correlation: 99.69 | Revenue CAGR: 45.58% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.07 | Chg30d=+65.81% | Revisions=+29% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.09 | Chg30d=+24.72% | Revisions=+50% | Analysts=5
EPS current Year (2026-12-31): EPS=0.33 | Chg30d=+71.53% | Revisions=+67% | GrowthEPS=+110.9% | GrowthRev=+25.8%
EPS next Year (2027-12-31): EPS=0.48 | Chg30d=+32.88% | Revisions=+44% | GrowthEPS=+45.9% | GrowthRev=+19.9%
[Analyst] Revisions Ratio: +68% (up=17, down=2)